A Direct Efficacy and Safety Comparison of Insulin Aspart, Human Soluble Insulin, and Human Premix Insulin (70/30) in Patients With Type 2 Diabetes
Authors:
- 1 May 2004
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (5) , 1023-1027
Abstract
OBJECTIVE—Because there are limited data on the comparison of insulin aspart and mixed insulin in type 2 diabetes, this trial was performed to compare the efficacy and safety of preprandial insulin aspart with human soluble insulin (HI) and human premix (70% NPH/30% regular) insulin (MIX). RESEARCH DESIGN AND METHODS—A total of 231 type 2 diabetic patients were randomized to insulin aspart (n = 75), HI (n = 80), or MIX (n = 76) for 3 months. Insulin aspart and HI were administered with or without bedtime NPH insulin. A total of 204 patients completed the trial according to protocol. HbA1c, 7-point blood glucose, insulin dosage, and hypoglycemic episodes were recorded. The primary end point was “change of HbA1c” from baseline to last visit. Analysis for equivalence was performed by t tests with three subtests. RESULTS—HbA1c decreased 0.91 ± 1.00 for insulin aspart, 0.73 ± 0.87 for HI, and 0.65 ± 1.10 for MIX with the following confidence intervals: insulin aspart HI (−0.21 to 0.57, P = 0.025), insulin aspart MIX (−0.17 to 0.69, P = 0.092), and HI-MIX (−0.33 to 0.48, P = 0.006). Postprandial blood glucose decreased in the insulin aspart group: 0.44 mmol/l to >1.67 mmol/l compared with HI and 1.1 mmol/l to >1.67 mmol/l compared with MIX. Preprandial insulin doses were similar in the insulin aspart and HI groups (10–14.5 U). Hypoglycemic events per month were 0.56 HI, 0.40 insulin aspart, and 0.19 MIX. CONCLUSIONS—Statistically, insulin aspart was not equivalent to another treatment in terms of HbA1c reduction. Insulin aspart treatment resulted in improved HbA1c and postprandial blood glucose. The application of insulin aspart was safe and well tolerated.Keywords
This publication has 28 references indexed in Scilit:
- Insulin aspart: promising early results borne out in clinical practiceExpert Opinion on Pharmacotherapy, 2002
- Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial)Experimental and Clinical Endocrinology & Diabetes, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjectsJAMA, 1997
- Comparison of Different Insulin Regimens in Elderly Patients With NIDDMDiabetes Care, 1996
- Time-action Profile of the Insulin Analogue B28AspDiabetic Medicine, 1996
- A Comparison of Premixed Insulin Preparations in Elderly Patients: Efficacy of 70/30 and 50/50 human insulin mixturesDiabetes Care, 1995
- Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDMDiabetes Care, 1995
- Comparison of Insulin With or Without Continuation of Oral Hypoglycemic Agents in the Treatment of Secondary Failure in NIDDM PatientsDiabetes Care, 1995
- Long-Term Improvement of Glycemic Control by Insulin Treatment in NIDDM Patients With Secondary FailureDiabetes Care, 1994